Off-Label Marketing Suit Costs Novartis $72M

Law360, New York (May 4, 2010, 6:44 PM EDT) -- Two Novartis AG units have agreed to pay $72.5 million to settle a whistleblower suit alleging they knowingly marketed the cystic fibrosis drug Tobi for uses not approved by the U.S. Food and Drug Administration.

Under the settlement, which was announced Tuesday by the U.S. Department of Justice and various state attorneys general, Novartis Vaccines & Diagnostics Inc. and Novartis Pharmaceuticals Corp. will shell out $43.5 million to the federal government, with the remaining $29 million to be shared by 49 states and the District of...
To view the full article, register now.